3D Tissue Models

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2006 Neoadjuvant Chemotherapy in Vulvar Cancer: Avoiding Primary Exenteration. Gynecol Oncol 100:53-57, 2006.
2. 2005 Topotecan in the Treatment of Elderly Patients with Relapsed Small Cell Lung Cancer. Clinical Lung Ca 7:190-6, 2005
3. 2003 Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study Gynecol Oncol 89: 267-270, 2003
4. 2003 A Phase II trial of a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer Gymecol Oncol 90: 64-69, 2003.
5. 2003 Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Therapy 10:224-238, 2003
6. 2003 The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clin Cancer Res 9:4139-4144, 2003
7. 2003 Mismatch repair gene expression defects contribute to microsatellite instability in ovarian Cancer. 98: 2199-2206, 2003
8. 2002 A Phase I/II trial of rAd/p53 (SCH 58500) Gene Replacement in recurrent ovarian cancer Cancer Gene Ther 9:553-566, 2002.
9. 2002 Failure of BRCA1 dysfunction to alter ovarian cancer survival Clin Cancer Res 8:1196-1202, 2002.
10. 2002 Preoperative serum vascular endothelial growth factor (VEGF) levels: significance in ovarian cancer Clin Cancer Res 8:3193-3197, 2002
11. 2002 Frequency of BRCA1 dysfunction in ovarian cancer J Natl Cancer Inst 94: 61-67, 2002.
12. 2002 Inactivation of BRCA1 and BRCA2 in ovarian cancer J Natl Cancer Inst 94(18):1396-1406, 2002.
13. 2002 Long term follow-up of patients with recurrent ovarian cancer after rAd p53 gene replacement with SCH 58500 Cancer Gene Ther 9:567-575, 2002
14. 2002 Quality of life and mood in women with gynecologic cancer Cancer 94(1):131-140, 2002.
15. 2001 Molecular determinants of ovarian cancer plasticity. Am J Pathol 158:179-1288, 2001.
16. 2001 The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer Clin Cancer Res 7:831-838, 2001
17. 2001 Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer Cancer Res 61:4371-4374, 2001
18. 2001 Ovarian cancer BRCA1 mutation detection: protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP). Human Mutat 18:337-344, 2001
19. 2001 The androgen receptor and DXS 15-134 markers reveal a high rate of discordance for germline X chromosome inactivation J Med Genet 38:474-478, 2001
20. 2001 P53 mutations and microsatellite instability in ovarian cancer: Yin and Yang. Am J Obstet Gynecol 184(5):891-903, 2001
21. 2000 Chromosomal abnormalities as prognostic factors in ovarian cancer. Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. Eur J Gynaecol Oncol 21(5):521, 2000
22. 2000 Glutathione s-transferase Mu polymorphism and their relationship with ovarian cancer Cancer Epidemiol Biomarkers Prev 9:587-590, 2000
23. 2000 Long-term central venous access in gynecologic cancer patients. J Am Coll Surg 191:403-409, 2000
24. 2000 The prognostic significance of p53 tumor suppressor gene alternations in ovarian cancer. Cancer 89(9):2006-2017, 2000
25. 1999 Association between non-random X-chromosome inactivation in germline DNA of patients with ovarian cancer J Natl Cancer Inst 91:339-346, 1999
26. 1999 Distant metastases in ovarian cancer: Why do they occur? Clin Cancer Res 5:2485-90, 1999
27. 1999 Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group Gynecol Oncol 75, 473-5, 1999.
28. 1998 A phase II trial of amonafide in patients with leiomyosarcoma of the uterus: A Gynecologic Oncology Group study Am J Clin Oncol 21:145-146,1998
29. 1998 Field cancerization: Why late recurrent ovarian cancer isn’t recurrent Am J Obstet Gynecol 178:641-649, 1998.
30. 1998 Vinblastine, ifosfamide, gallium nitrate, and filgrastim in platinum- and paclitaxel-resistant ovarian cancer: a phase II study. Am J Clin Oncol 21(3): 287-290, 1998.
31. 1998 Optimization of PCR and Electrophoresis Conditions Enhances Mutation Analysis of the BRCA1 Gene Molec Genet Metab 64:173-176, 1998
32. 1997 Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res 57:1047-1049, 1997
33. 1997 A phase II trial of amonafide in patients with nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study Am J Clin Oncol 20:26-27,1997.
34. 1996 Genomic instability in ovarian cancer: A reassessment using an arbitrarily primed polymerase chain reaction Oncogene 13:2499-2504, 1996
35. 1996 An abundance of p53 null mutations in ovarian carcinoma Oncogene 13:117-123, 1996
36. 1996 CA125 kinetics: a cost effective clinical tool to evaluate clinical trial outcomes in the 1990s Am J Obstet Gynecol 174:1241-1254, 1996
37. 1995 Absence of significant germ line p53 mutations in ovarian cancer patients Gynecol Oncol 58:368-374, 1995
38. 1995 Isolation and preliminary characterization of an ovarian carcinoma cell line from a patient with familial ovarian cancer Gynecol Oncol 56:39-44, 1995
39. 1992 Conservative surgical management of dysgerminoma in pregnancy. Obstet Gynecol 79:887-890, 1992
40. 1991 CA125 regression: A model for epithelial ovarian cancer by response. Am J Obstet Gynecol 165:360-367, 1991
41. 1990 An ovarian tumor marker, CA125, comes of age West J Med 152:406-407, 1990.
42. 1976 Progesterone binding components of chick oviduct XIV. In vitro effect of receptor subunits on gene transcription J Biol Chem 251:5178-5186, 1976
43. 1975 Tumoricidal steroids: A potential cure for advanced breast and prostatic cancer Texas Med 71:86-91.6, 1975

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.